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The members of the p38 subfamily of Mitogen-Ac-
tivated Protein Kinases (MAPKs) are a versatile
group of proteins, that function as signal transdu-
cers involved in key cellular functions. Initially, p38
MAPKs were associated with inflammatory and ce-
llular stress responses and, as such, p38 has been
an important target for anti-inflammatory thera-
pies. Recently, increasing evidence has directly im-
plicated p38 MAPKs in processes essential for cell
development, transformation and tumorogenesis,
namely: proliferation, differentiation, apoptosis, in-
vasion and metastasis. These features make p38
MAPKs potential targets for future anti-neoplastic
therapies.
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Participación de MAP quinasas p38 en
carcinogénesis
Los componentes de la subfamilia p38 de quinasas
activadas por mitógenos (MAP quinasas) constitu-
yen un grupo de proteínas muy versátiles, que actú-
an como transductoras de señales en funciones ce-
lulares de capital importancia. Originalmente las
proteínas p38 han sido asociadas con respuestas in-
flamatorias y de estrés celular, debido a lo cual p38
se ha convertido en una diana terapéutica de espe-
cial relevancia en el control de enfermedades aso-
ciadas a estos procesos.
No obstante, actualmente existen evidencias consi-
derables para también implicar directamente a p38
en eventos de capital importancia dentro de la
transformación celular y la tumorogénesis, en con-
creto: proliferación, diferenciación, apoptosis, inva-
sión y metástasis. Estas propiedades de las MAP
quinasas p38 las convierten en potenciales dianas
para futuras terapias antineoplásicas.
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regulated kinases), JNK/SAPKs (c-jun N-terminal ki-
nase/stress activated protein kinases), ERK5/BMKs
(Big MAP kinases) and p38 MAPKs1,2. Even though the
activation of the different MAPKs was originally asso-
ciated to defined types of stimuli, it is now clear that
most stimuli can switch on several MAPK modules
and that the biological outcomes of such stimuli are
consequences of the integration of the intensity and
duration of the signals transduced by each individual
MAPK route. The biological mechanisms involved in
cellular transformation and oncogenesis are no excep-
tion and, to date, all MAPKs have been found to be in-
volved, one way or another, in distinct aspect of carci-
nogenesis. This review will focus in the role played by
p38 MAPKs in those processes that turn awry at some
stage of the malignification process.
THE p38 MAPK FAMILY
p38a /CSBP2/RK2 was first identified as an endoto-
xin-stimulated kinase3. At the same time, a target for
imidazole anti-inflammatory drugs was identified,
Mitogen-activated protein kinases (MAPKs) are cyto-
plasmic serine/threonine kinases that are activated 
in response to a wide array of extracellular stimuli, in-
cluding those that regulate cell proliferation, differen-
tiation, development and inflammation. MAPKs are pi-
votal elements in the transduction of signals from the
membrane to the interior of the cell, acting as essen-
tial mediators in signalling modules that include se-
quentially: MAP kinase kinase kinases (MAPKKKs),
dual-specificity MAP kinase kinases (MAPKKs) and
MAPKs. To date, four mammalian MAPKs families ha-
ve been studied in detail: ERKs (extracellular signal
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TABLE 1. Main features of p38 family members
Member Identification Splicing Tisular Imidazole Activating Substrates Special features
isoforms distribution response stimuli
p38 a
CSBP2
RK2
CSBP2 had great
homology with yeast
protein HOG. It was
identified by several
approaches4
A 25 residue internal
sequence makes
CSBP1 different from
CSBP2. CSBP1
complements HOG 1
deletion in yeast. 
Mxi212 and Exip13
are two other
alternative splicing
products
p38a is
ubiquitous and
the rest of the
isoforms present
a more restricted
pattern of
expression. Mxi2
appears to be
only expressed
in kidney24
CSPB2 activity
is inhibited by
imidazoles, but
Mxi2 isn´t25
This kinase is
activated by 
IL-1b , TNF-a ,
sorbitol (osmotic
shock) or UV
radiation. 
Both MKK3 and
MKK6 can
activate it2
It phosphorylates
MBP, ATF-2,
MAPKAP-K2,
MAPKAP-K3, MNK,
MSK , CHOP, PRAK,
MEF2C and Max,
but not c-Jun, as the
rest of p38 family
members. Sap-1a y
Elk-1 are also good
substrates16-23
CSBP2 is the most
abundant isoform
of the family and
has been more
extensively studied
In 1996 Jiang et al
described the
cloning and
characterization of
this family member
with 74% homology
with p38a
Kumar et al tried to
clone p38 b by RT-
PCR using Jiang et
al sequence, but the
cDNA obtained had
an internal delection
of 8 aa , which they
named p38b 27
Similar pattern of
distribution as
p38a , being
expressed in
kidney, pancreas,
muscle, spleen,
lung, placenta,
heart and brain
It´s kinase
activity is
inhibited by
imidazole
compounds5
It is activated by
the same kind of
stimuli as p38a ,
showing a slower
activation kinetics.
It is not activated
by phorbol esters.
MKK6 can
activate it
although MKK3
cannot5
MBP, ATF-2,
MAPKAP-Kinase 2,
MAPKAP-Kinase 3
are good substrates,
but not c-Jun7
The extra and
unique 8aa p38b
are an insertion
when comparing
with the rest of
MAPKs, so p38 b 2
has more
correlated
sequence when
compared with the
other family
members7
In 1997, Stein et al
described a new
isoform, p382,
identical to p38b
except in 3
aminoacids14
This isoform was
isolated in three
different forms, two
of them have no
phosphorylation
motif
It´s expression
pattern differs
from p38a , being
most abundant in
heart and testes
and less
abundant in
placenta and
ovaries14
It´s activity can
be inhibited by
imidazoles as
much as p38a
Stein et al showed
that anisomycin,
UV and sorbitol
activated this
kinase. MKK6 is
also a good
activator. 
It can phosphorylate
ATF-2, Elk-1 and
Sap-1a. 
It´s remarkable
that ATF-2 is 180
times better
substrate for p382
than for p38a 14
p38b
p382 
p38g
SAPK4 
Han et al described
this kinase in 1996
after identifying it in
Gen Bank. It´s 63%
homologous to p38a
and 62% to p38b
Not described 
so far
mRNA of this
isoform is just
found in skeletal
muscle, which
suggests a
specific function
in this tissue10
Kumar et al
found that this
kinase cannot be
inhibited by
imidazoles, due
to mutations in
aminoacids 106,
107 and 108 with
respect to p38a 7
It´s activated by
typical stress
stimuli, such as IL-
1, TNF-a , sorbitol,
UV and it is also
activated by PMA.
It´s not regulated
by insulin, serum
and okadaic acid
and it is activated
by ortovanadate7
It can phosphorylate
ATF-2 , and
MAPKAP K3, but it
is unable to
phosphorylate
MAPKAP K210
Lechner et al
showed that this
isoform works as a
signal transducer
during
differentiation from
myoblasts to
myotubes in
C2C12 cells. This
kinase favours
nuclear myotubular
fusion rate, which is
a sign of
differentiation26
p38d
ERK6
In 1997, Jiang et al
cloned and
characterized this
member. This
isoform is 60%
homologous to
p38a 6
They haven´t been
described
The study of its
mRNA revealed
a higher
expression in
kidney and lung6
Kumar et al
showed that this
kinase is not
inhibited by
imidazoles7
It´s activated by:
anisomycin, PMA,
arsenite, PAF,
oxidative stress,
TNF-a , IL-1,IL-6
and UV. Neither
serum, insulin, or
EGF have any
effect on its
activity6
It can phosphory-
late MBP, ATF-2,
Elk-1 and MAPKAP
K 3, 
but not 
MAPKAPK 26
It seems that p38
and p38d have
evolved towards a
different subclass
of p38 MAPK which
differ from p38 a
and from p38b ,
having a more
restricted tisular
distribution,
Greater
susceptibility to
PMA, A different
substrate
specificity, and a
different sensibility
to imidazoles6.
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that actually turned up to be p38 a 4. Since then, other
three p38 isoforms have been described: p38, b ,
g /SAPK4, and d /ERK65-10. Also, splicing variants of
p38a and p38b , namely CSBP1, Mxi2, Exip11-13, p38-2
and p38b 2 have been reported7,14.
p38 MAPKs are substrates for the dual-specificity kina-
ses MKK3 and MKK6 and to a lesser extent for MKK4.
Likewise, p38 MAPKs are activated by an ever-growing
number of upstream MAPKKKs and MAPKKKKs2. Al-
so, in a fashion similar to SAPK/JNKs, the cascade that
leads to p38 activation is regulated at its origins by Rho
family GTPases1.
Once activated, p38 MAPKs can phosphorylate a
number of cytoplasmic proteins like cPLA215 and ki-
nases like MAPKAPK 2/316 MSK17, MNK18 and
PRAK19. In addition, p38 MAPKs translocate to the
nucleus where they phosphorylate a broad range of
transcription factors like those of the Ets20, ATF21,
MEF22 and GADD23 families among others. The acti-
vation of these downstream mediators sets in motion
the cellular processes and genetic programs ultima-
tely responsible for the biological outputs regulated
by p38 MAPKs. The main features of p38 isoforms are
summarized in table 1.
p38 MAPKS AND CANCER
Even though p38 MAPKs cannot be considered onco-
genes sensu stricto, as they cannot induce cellular
transformation, mounting evidence associate the acti-
vation of the p38 pathway to many aspects of carcino-
genesis. With respect to MAPKs, oncogenic transfor-
mation and tumour progression has been traditionally
linked to the aberrant function of the Ras/ERK path-
way27. However, it is becoming clear that JNK and
p38 MAPKs also play an important role in transfor-
mation under some circumstances. A clear case is
exemplified by the oncogene mas encoding for a G
protein-coupled receptor that induces transformation
mediated by the activation of the JNK/p38 cascades
but with no concomitant activation of ERK28. Another
example is the herpes virus associated to Kaposi´s
Sarcoma HHV8, that also expresses a G-coupled re-
ceptor capable of activating both JNK and p38 and
provokes cellular transformation and activates angio-
genesis29.
Constitutive activation of the p38 pathway can be de-
tected in different types of tumours. Some studies re-
ported high levels of p38 (p38 refers to p38 a hereaf-
ter, unless otherwise indicated) kinase activity in
non-small cell lung carcinomas30. In human breast
tumours analyzed for the expression of p21-activated
kinase (PAK), p38 and MAPKAPK-2, all these proteins
were overexpressed and exhibited increased activity31.
Activation of p38 was significantly elevated in well-
differentiated prostatic tumours. Furthermore, prosta-
tic intraepithelial neoplastic lesions exhibiting activa-
ted p38, were observed to be proliferative rather than
apoptotic32. p38 also appears to be determinant for
the progression of multiple myelomas33. Also, in a cell
culture model of ovarian epithelium, activation of sig-
nalling proteins, particularly those of the MEK6/p38/
MAPKAPK-2 pathway and the PI3K pathway, were
found to correlate with phenotypic manifestations of
progressive stages in the development of ovarian can-
cer34. All these cases clearly associate p38 to malig-
nancies. Something that should come as no surprise,
as in these past years evidence has mounted relating
p38 activation to many essential processes in the up-
bringing of cellular transformation and tumoral pro-
gression.
p38 IN APOPTOSIS/CELL SURVIVAL
Apoptosis is one of the main safeguards against un-
controlled cell proliferation, by getting rid of those
cells that are no longer useful. Apoptosis can be pro-
moted by multiple intra and extracellular signals
such as DNA damage, deprivation of growth factors
or activation of death receptors35. p38 activation has
been associated to apoptosis caused by diverse stimu-
li in many cellular models27. In diverse cell types,
overexpression of upstream components of the p38
cascade is sufficient to induce apoptosis. Fibroblasts
transfected with activated MEKK1 die by apoptosis36
and T cells expressing activated Cdc42 have increa-
sed JNK/p38 activation and undergo apoptosis due to
augmented caspase activity37. ASK1 (apoptosis signal
kinase1) can activate p38 direct activators MKK4 and
MKK3/6 and when overexpressed, is a potent induc-
tor of cell death38.
In these cases apoptosis induction required massive
activation of p38, that may not be reminiscent of a
physiological situation. However, a large body of evi-
dence indicates that, at physiological levels, most
apoptogenic stimuli are accompanied by p38 activa-
tion. Ceramide mediates in apoptosis induction res-
ponding to diverse stimuli including TNF, TGF and
Fas-Ligand27. p38 activation seems to be a key event
in this process since chemical inhibitors for p38 block
apoptosis induced by ceramides39. Apoptosis induced
by heat shock is also associated with JNK/p38 activa-
tion. High levels of heat shock protein Hsp70, protects
against cell death, partly by inhibiting JNK/p38 acti-
vation40. 
On the other hand, anti apoptotic stimuli and agents
tend to prevent p38 activation. Insulin has neuropro-
tective effects in foetal neurons. In these cells, insulin
specifically inhibits p38 activity41. In a similar fashion,
UV light-induced apoptosis can be blocked by the ex-
pression of the dual specificity phosphatase MKP-1
which decreases JNK/p38 activation42. Suppression of
serum deprivation-induced apoptosis in NIH3T3 by
TGF-b is also exerted through the inhibition of p3843.
322 Rev Oncol 2003;5(6):320-30 24
SANZ-MORENO V, CRESPO P. p38 MITOGEN-ACTIVATED PROTEIN KINASES:THEIR ROLE IN CARCINOGENESIS
Likewise, expression of dominant negative MKK3
blocks cisplatin-induced apoptosis44.
Although p38 was initially described as an apoptosis-
inducing kinase38, recent evidence show that depen-
ding on the cell type and the apoptogenic stimuli, p38
can act, not only as positive regulator of cell death,
but also as a negative one. On one hand, in PC12
cells, p38 activation favours NGF deprivation-induced
apoptosis45. On other cell types like cardiomyocytes,
p38 activation can protect from apoptosis induced by
anisomycin46. Likewise, in endothelial cells where
TNF-a produces inflammation rather than apoptosis,
TNF stimulates p38 with bimodal kinetics, interrup-
tion of early p38 activation can enhance TNF-a -indu-
ced apoptosis, suggesting a protective role for p3847.
Moreover, the activation of the p38 substrate MEF2C,
is necessary for neuron survival, unveiling a direct
link between survival and p38 activation48. Adding
more complexity to the regulation of pro and anti
apoptotic functions by p38 family members, there are
some studies that provide evidence for differences
between p38 isoforms when regulating apoptotic pro-
cesses. In cardiomyocytes and Hela cells, p38 a indu-
ces apoptosis while p38b promotes cell survival49.
Furthermore, p38 b but not p38 a can protect mesan-
gial cells from TNFa -induced apoptosis50.
Currently, the prevailing line of thought is that, rather
than the activation of a single, discrete route, what ul-
timately determines whether a cell survives or under-
goes apoptosis is the dynamic balance between survi-
val and stress signals. The first evidences on this
respect, were provided by Xia et al, that found that in
PC12 cells the induction of apoptosis depended on the
relative contributions of JNK/p38 and ERK activities.
In these cells, apoptosis caused by NGF withdrawal
was accompanied by a sustained activation of JNK/p38
and the inhibition of ERK51. A similar case was obser-
ved in sympathetic neurons overexpressing MEKK1.
Once again, tilting the balance of relative activities to-
wards p38/JNK in comparison to ERKs, resulted in
apoptosis51. On the other hand, transient activation of
ERK induced by EGF stimulated proliferation, whe-
reas prolonged ERK activation by NGF induced neu-
ronal differentiation, in both cases JNK/p38 activity
levels were low52,53. An analogous situation was ob-
served in the case of constitutively active ASK1,
which potentiates apoptosis in NGF-differentiated
PC12 cells and rat sympathetic neurons, while a do-
minant negative ASK1 reduces apoptosis. However, in
undifferentiated PC12 cells, moderate expression of
ASK1 induces neural differentiation through the acti-
vation of p3854,55. These results suggest that a strong
activation of ASK-p38 pathway leads to apoptosis,
whereas a milder activation would lead to differentia-
tion. These situations also illustrate that the (relative)
activation intensity of a MAPK route is not the sole
factor in the decision of cell fate. In addition, the du-
ration of the signal is also determinant. As such, in
PC12 cells, early/transient and late/sustained activa-
tion of JNK/p38 induced by TNF-a have been repor-
ted to correlate with survival/differentiation or with
apoptosis, respectively56,57.
This interplay among survival pathways, like ERK, and
pro-apoptotic pathways such as p38, is highlighted by
many anti tumoral drugs, whose mode of action is the
induction of apoptosis in the targeted cells. As such,
flavopiridol induces apoptosis in chronic lymphocytic
leukaemia B-cells by activating p38 and suppressing
ERK activity58. An identical situation is observed in
leukemic U937 cells induced to undergo apoptosis by
arsenic trioxide59. Lastly, taxol ability to induce apop-
tosis in different cell types is intimately dependent on
its capacity to activate p38 and suppress ERK60,61.
One important question is: how does p38 activation set
in motion the machinery responsible for executing
apoptosis? Even though this issue remains largely
unanswered, the emerging picture, somewhat expec-
ted, is that there is not a single culprit. As such in renal
cells, p38 mediates cell growth arrest and apoptosis 
through the transactivation of GADD45 and GADD153
(Growth Arrest and DNA Damage inducible gene)62. In
response to UV light, p38 stimulates the transcriptional
activity of p5363, p38 also regulates the activation of
p53 in response to genotoxic stress and inhibition 
of p38 reduces p53-mediated apoptosis induced by
chemotherapeutic agents64. In chondrocytes, nitric oxi-
de-induced apoptosis is dependent on p38 activation,
that induces the accumulation of p53 via NF-k B-de-
pendent transcription and its stabilization by direct
phosphorylation65. A similar situation is observed in
UV-induced apoptosis in keratinocytes66. An inhibitor
of cell cycle progression, the p53-inducible phosphata-
se Wip1 mediates a negative feedback regulation on
p38 signalling in response to UV, by dephosphorylating
p3867. Inactivation of p38 by Wip-1 facilitates tumour
formation68. Accordingly, there are recent reports sho-
wing that Wip1 is overexpressed in breast tumours69.
Other mechanisms are also known to intervene in
p38-mediated apoptosis: ASK1 was reported to execu-
te apoptosis mainly by mitochondria-dependent cas-
pase activation70. In this context, a large body of data
suggests that p38 activation results in cytochrome C
release from mitochondria and subsequent activation
of caspases 3 and 871,72, that can be specifically bloc-
ked by p38 pharmacological inhibitors73-76. In light of
all these data it becomes evident how by altering p38
activation status some cells may subvert pro-apopto-
tic mechanisms as a route to immortalization and tu-
moral growth.
p38 MAPKS IN DIFFERENTIATION 
It is well established that apoptosis, proliferation and
differentiation are intimately linked processes gover-
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vious reports had suggested that sustained activation
of the ERK pathway was sufficient for PC12 differen-
tiation. This was based on the induction of differen-
tiation, in the absence of NGF, by expression of a
constitutively active mutant of MEK184. It now appe-
ars that expression of constitutively active MEK1 can
also activate p38 and that SB203580 can block MEK1-
induced neurite outgrowth, even though ERK would
still be active. However, sustained activation of p38 is
not very efficient for inducing neurite outgrowth in
PC12 cells, except when combined with EGF stimula-
tion, which induces transient activation of both ERK
and p38. Based on these results, it has been proposed
that neuronal differentiation of PC12 cells might re-
quire a sustained activation of either ERK or p38
MAPKs, combined with the transient activation of the
other MAPK85. 
5) Osteogenic differentiation. p38 plays an important
role in osteoblast differentiation in several cell sys-
tems. p38 and ERK are activated as calvarial osteo-
blast differentiate into mature osteocytes. When p38
was inhibited with pyridinil imidazoles, the expres-
sion of differentiation markers, such as alkaline
phosphatase (ALP) and mineral deposition, were sig-
nificantly reduced. MC3T3-E1 osteoblastic cells ex-
pressing dominant negative p38 also displayed a dela-
yed mineral deposition and reduced ALP activity.
Finally, differentiation of bone marrow osteoprecur-
sors was also impeded by the p38 MAPK inhibitor, as
justified by the same markers of osteogenic differen-
tiation86.
6) Chondrogenic differentiation. ATDC5 cells are dif-
ferentiated by Growth/Differentiation factor-5 (GDF-5)
that induces a potent activation of p38 and ERK.
Phosphorylation of p38 was also induced by BMP-2
and TGF-b 1. An inhibitor of p38 a and p38 b ,
SB202190, caused complete inhibition of cartilage no-
dule formation induced by GDF-5, but failed to affect
ALP activity. Expression of the type II collagen, a hall-
mark of chondrogenesis, was also induced by GDF-5
and strongly suppressed by SB202190. On the other
hand, although the inhibitor of ERK, PD98059, bloc-
ked the phosphorylation of ERK by GDF-5, it inhibi-
ted neither ALP activity nor cartilage nodule forma-
tion87. Treatment of chicken mesenchymal cells with
cytochalasin D disrupted the actin cytoskeleton with
concomitant chondrogenic differentiation88. The
chondrogenic process was accompanied by an incre-
ase in p38 activity and inhibition of p38 with SB203580
blocked this process88.
7) Erythroid differentiation. Erythroid differentiation
of K562 cells induced by cyclosporin A89, and of SKT6
cells induced by erythropoietin (Epo)90 is mediated by
p38. ERK1-2, p38 and JNK-2 were rapidly and tran-
siently activated by Epo. However, only SB203580 but
not PD98059 could suppress Epo-induced differentia-
tion. SB203580 also prevented cyclosporinA-induced
324 Rev Oncol 2003;5(6):320-30 26
ned by common mechanisms. As such, growing evi-
dence also involve p38 in differentiation processes in
various cellular systems: 
1) Adipocytic differentiation. In 3T3 L1 fibroblasts
adipocytic differentiation induced by insulin was
blocked by p38 inhibitory mutants or by the p38 spe-
cific inhibitor SB203580. Conversely, expression of a
constitutively active mutant of MKK6 induced adi-
pocytic differentiation77. The transcription factors
CCAAT/enhancer-binding protein b (C/EBPb ) and
peroxisome proliferator-activated receptor (PPARg )
might be the likely p38 targets during adipogenesis.
p38 inhibitors strongly reduce the expression of
PPARg and the amount of C/EBP b 78. Furthermore, it
has been demonstrated that p38 inhibitors block the
differentiation of mesenchymal C3H10T1/2 cells into
adipocytes induced by bone morphogenetic protein 2
(BMP2), essentially by preventing the transcriptional
activation of PPAR g 79.
2) Myogenic differentiation. In C2C12 cells, depriva-
tion of growth factors results in myogenic differentia-
tion, that correlates with elevated p38 activity80. Mo-
reover, treatment with SB203580 retards myoblast
elongation and alignment, prevents myoblast fusion
to form multinucleated myotubules, and inhibits the
expression of muscle-specific genes. p38 regulates
MyoD, a transcriptional activator essential for myoge-
nesis, by two mechanisms: augmenting its levels by
increasing its transcription, regulated by the p38
substrate MEF2C, and by increasing its stability th-
rough direct phosphorylation81. It has also been des-
cribed how activation of p38 induces cell cycle arrest
via the inhibition of Raf/ERK pathway during muscle
differentiation in myoblasts, by as yet unknown me-
chanisms82.
3) Cardiac hypertrophy is an adaptative response of
the heart to a variety of intrinsic and extrinsic stimuli.
The hypertrophic response, during which cardiom-
yocytes increase in size without undergoing cell divi-
sion, initially serves to compensate for decreased car-
diac output; however, prolonged hypertrophy can
become detrimental, resulting in dilated cardiomyo-
pathy and heart failure91. p38 activity was signifi-
cantly increased in mouse hearts after chronic aortic
constriction, coincident with the onset of ventricular
hypertrophy92. Infection of cardiomyocytes with ade-
novirures expressing, MKK3 and MKK6 elicited cha-
racteristic hypertrophic responses, including an in-
crease in cell size, enhanced sarcomeric organization,
and elevated atrial natriuretic factor (ANF) expres-
sion. The direct involvement of p38 in cardiac hyper-
trophy suggests a significant role for p38 in the pat-
hophysiology of heart failure.
4) Neuronal differentiation. Treatment of PC12 cells
with SB203580 or transfection with p38/MKK6 inhi-
bitory mutants originate a profound inhibition of
NGF-induced neurite outgrowth83. Conversely, pre-
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haemoglobin synthesis in K562 cells, while another
MEK inhibitor U0126, enhanced it, suggesting that
activation of p38 and inactivation of ERK are involved
in erythroid differentiation89.
p38 IN PROLIFERATION
When referring to the regulation of proliferative pro-
cesses, the general rule would be that there is no ge-
neral rule, as p38 exhibits the same phenomenology
previously described for differentiation and apoptosis.
It can exert either a positive or a negative control de-
pending on the cell type and the mitogenic stimulus
in question. There is now ample evidence to assert
that p38 activation favours proliferation in several ce-
llular systems.
Using specific inhibitors for MEK and p38, it was de-
monstrated that both ERK and p38 are critically in-
volved in the transduction of a proliferative signal
and cooperate in G-CSF-induced cell proliferation in
hemopoietic cells93. Factors that promote T cell proli-
feration IL-2 and IL-7, activate both JNK and p38. In-
hibition of p38 with pyrinidyl imidazoles correlated
with suppression of IL-2/7-driven T cell prolifera-
tion94. In both cases, the proliferative effect of p38 ac-
tivation was mediated by its substrate MAPKAP-K2.
There is also evidence that p38 can be activated by ot-
her hemopoietic growth factors, including Steel locus
factor, colony stimulating factor-1, granulocyte/ma-
crophage-colony stimulating factor, interferons and
interleukin-395.
In Swiss 3T3 fibroblasts and PC12 cells, FGF-2 activa-
tes ERK with similar kinetics. By contrast, in PC12
cells p38 is activated weakly and transiently, while a
much stronger and sustained activation of p38 is seen
in FGF-2-treated fibroblasts. Inhibition of ERK blocks
differentiation but has little effect on proliferation.
Contrarily, inhibitors of p38 block proliferation but
have no effect on differentiation96.
On the other hand, and to complicate things further,
p38 can behave as an antagonist of mitogenic signa-
lling. This is best exemplified by the relationship
among p38 and the components of the Ras/ERK path-
way, reminiscent of the situations observed in the re-
gulation of apoptosis though, quite expectedly, with
opposed effects. In some cells like NIH3T3, p38 can
be activated by Ras and this activation provides a ne-
gative feedback for Ras proliferative signalling97. In
agreement, in primary human fibroblasts Ras induces
premature senescence through sequential activation
of the MEK-ERK pathway and the MKK3/6–p38 path-
way98. Also, ectopic expression of MEKK3 induces G1
arrest and reverses Ras-mediated transformation in
NIH3T3 fibroblasts by downregulating cyclin D199.
Recent reports go a bit further, suggesting that down-
regulation of p38 is an essential requirement for Ras-
induced transformation100.
Interactions between Ras/ERK and p38 MAPKs beco-
me even more complex when the different p38 iso-
forms are taken into account. A new twist has been
recently provided by the direct interaction between
p38 and ERK MAPKs as a mechanism for regulating
ERKs functions. p38 can bind to ERK and this inte-
raction downregulates ERK phosphorylation state101.
Interestingly, Mxi2, a p38 a splice isoform with a stri-
king sensitivity to growth factor stimulation25 can al-
so bind to ERK1/2, but as opposed to p38, upregulates
its nuclear activity by sustaining its phosphorylation
levels in the nucleus but not in the cytoplasm102. Sin-
ce Mxi2 and p38 are splice variants of the same gene,
this opens an attractive scenario in which, by swit-
ching the splicing taking place at the p38 locus, the
signalling machinery could be programmed to up-or
down-regulate ERK activity, with its subsequent alte-
rations on the proliferative/survival signals resulting
from ERK activation.
p38 IN THE REGULATION OF CELL CYCLE
PROGRESSION 
At this stage, it should come as no surprise that pro-
teins with such profound effects on proliferation, diffe-
rentiation and apoptosis should impinge significantly
on the machinery that regulates cell cycle progression.
The first evidences were obtained in CCL39 cells and
in NIH3T3 fibroblasts in which p38 negatively regula-
ted cell cycle progression in the G1/S transition, me-
diated by the inhibition of cyclin D1 expression. In
cells expressing high levels of MKK3, a significant in-
hibition of mitogen-induced cyclin D1 expression was
observed. Accordingly, inhibition of p38 with SB203580
augmented cyclin D1 protein levels103. Cyclin D1 se-
ems to be one of the favoured targets for p38-mediated
control but other cell cycle checkpoints are also sub-
ject to p38 regulation.
Regarding the G1/S transition, the Rho GTPase Cdc42
can inhibit cell cycle progression at G1/S through a
mechanism requiring the activation of p38104. Likewi-
se, a constitutively active MKK6 is also capable of in-
ducing cell cycle arrest on G1 and senescence in a
p38-dependent fashion105. The growth-inhibitory ef-
fects of TGF- b are at least partially mediated by the
TAK1-MKK6-p38K pathway. In renal tubular cells
promoter activities in cyclins D1 and A genes and cell
cycle progression are negatively regulated by the
TAK1-MKK6-p38 pathway and positively regulated by
the MEK-ERK pathway106.
The G2/M checkpoint is also under the influence of
p38 regulation. Indeed, recent reports indicate that
regulation by p38 of the phosphorylation of the
phosphatase Cdc25B is a critical step at this check-
point63. Another isoform p38g , is required for gamma-
irradiation-induced G2 arrest. Activation of the
MKK6-p38g cascade is sufficient to produce a halt at
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the G2/M transition, while the expression of domi-
nant negative MKK6 or p38g allows cells to escape the
DNA damage-induced G2 arrest. p38 g effects are me-
diated by Cds1/Chk2107. In a similar fashion, in
CCL39 and Rat-1 cells, MEKK3 induces cell cycle
arrest at G2/M by a mechanism dependent on p38 a /b
that involves the up-regulation of p21 and the inhibi-
tion of cyclinA/Cdk2 and cyclinB/Cdk1108.
In the metaphase/anaphase or mitotic spindle check
point p38, but not ERK or JNK, is activated when
cells are arrested in M phase by the disruption of the
spindle with nocodazole. Injection of activated p38 in-
to cleaving Xenopus embryos induced mitotic arrest.
Treatment of NIH 3T3 cells with a inhibitor of p38
compromised the spindle assembly checkpoint func-
tion, suggesting that p38 is essential in this process in
somatic cell cycles109. Persistent activation of p38
blocks foetal thymocyte development at the
CD25(+)CD44(-) stage, but inactivation of p38 is re-
quired for further differentiation into CD4(+)CD8(+)
thymocytes. The arrest in mitosis is partially respon-
sible for the blockade of differentiation. Highlighting
that p38 is a critical regulatory element of differentia-
tion and proliferation during the early stages of thy-
mocyte development110. There are also studies under
physiological conditions that show how p38 is activa-
ted during normal mitosis in retinal neuroblasts. The
cell cycle in the proliferative zone of the retina is
tightly controlled and proceeds in synchrony with in-
terkinetic migration of the neuroblast nuclei. Mitotic
profiles in the developing retina are highly enriched
in phosphorylated p38. Blockade of p38 activity with
SB203580 transiently arrested neuroblasts at the me-
taphase-anaphase transition, while prolonged p38 in-
hibition induced cell death. p38 inhibition also indu-
ced an aberrant mitotic profile, with polarized
chromosomes. Suggesting that p38 is required for
proper cell cycle progression during the metaphase-
anaphase transition111.
INVASION AND METASTASIS
Once cellular transformation has taken place, a series
of processes must ensue before full-blown cancer de-
velops, namely: migration from the primary site and
invasion of sorrounding tissues. Intravasation and dis-
semination through the vascular system. Neocoloniza-
tion at distant sites and secondary, metastatic growth,
that in a similar fashion to the growth of the primary
tumour, also requires neovascularization. p38 is also
involved in most of these processes.
Migration of miocytes induced by PDGF can be bloc-
ked by p38 inhibitors, in a process mediated by
HSP27 and F-actin polimerization112. Likewise, incre-
ased migration of lung endothelial cells induced by
Heregulin is p38-dependent, as SB203580 can readily
inhibit the process113. Once again, a cross talk betwe-
en p38 and ERK pathways seems determinant in the
regulation of migration, as it is the ratio between the
activities of these two kinases what dictates the mi-
gratory propensity of epithelial cells114.
Migration and subsequent invasion of sorrounding
tissue requires the destruction of the extracellular
matrix and underlying basal laminas enclosing the
primary growth. In these processes, the secretion of
proteases cocktails from the tumour cells plays an es-
sential role. A large body of evidence point to p38 as
an important regulator of protease synthesis and se-
cretion. In malignant melanoma cells a p38 inhibitor
blocked the expression of matrix-metalloproteinase
(MMP-2) and reduced the invasive potential of these
cells115. In squamous cell carcinoma cell lines, phor-
bol ester-enhanced secretion of metalloproteinase 9
(MMP-9) and in vitro invasiveness, correlated with a
strong activation of p38116. Expression of collagenases
3 (MMP-13) and 1 (MMP-1) in transformed kerati-
nocytes are also p38-dependent (117). Apparently, the
activation of p38 enhances MMP-1 and stromelysin
(MMP-3) expression by stabilizing their mRNA118. 
Once dissemination through the vascular system and
extravasation have taken place, cancer cells may either
resume growth, leading to overt metastasis, or enter a
state of protracted dormancy. ERK/p38 activity ratio
predicts whether the cells will proliferate or enter a
state of quiescence. In breast, prostate, melanoma, and
fibrosarcoma cell lines, the level of active ERK and the
ERK/p38 activity ratio predict for this behaviour in ap-
proximately 90% of the cell lines tested. Modulation of
ERK/p38 activity ratio by multiple pharmacological
and genetic interventions confirms that low p38/ERK
ratio promotes tumor growth, whereas a high
p38/ERK ratio favours proliferative arrest119.
p38 MAPKs can also be pivotal elements in the
growth of primary tumours and in the metastatic pro-
cess by virtue of their role as regulators of vasculari-
zation. As a proof of it, p38 has been found to be acti-
vated in response to Vascular Endothelial Growth
Factor (VEGF) in endotelial cells, in which p38 acti-
vity is also required to regulate cellular migration120.
Angiogenesis induced by TNF- a is partly mediated by
ephrin A1. In endothelial cells, ephrin A1 induction
can be blocked by pyridinyl imidazoles121. In a simi-
lar fashion, VEGF secretion is upregulated by IL-1 in
human vascular smooth muscle cells by a mecha-
nism involving p38122. Lastly, the Kaposis sarcoma-
associated herpesvirus G protein-coupled receptor, a
potent stimulator of neovascularization and angioge-
nesis, upregulates VEGF expression and secretion
with the participation of ERK and p38 pathways123.
CONCLUSIONS AND PERSPECTIVES 
At this stage, it is undoubted that MAPKs play key role
in the processes that bring about malignification.
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Thus, modulating the activities of MAPKs as a means
to prevent tumoral growth and progression is now a
widespread anti neoplastic strategy at its initial sta-
ges. Indeed, it is clear that the activities of MAPKs, in
particular p38, are subject to regulation upon exposu-
re to diverse classes of anti tumoral agents. With in-
creased evidence supporting a role for MAPK signa-
lling in antitumour drug action, p38 regulators may
have an enormous potential as chemotherapeutic
drugs themselves or as chemosensitizing agents. Ho-
wever, it is becoming clear that these responses tend
to be context-dependent, and can differ enormously
depending on the cellular system and conditions. The
biological outcomes of p38 activation/inhibition may
be completely different depending on the cell type
and subtle variations when interfering with the inten-
sity and duration of p38 signals can result in profound,
unexpected and sometimes unwanted effects. Therefo-
re modulation of p38 as an anti tumoral strategy, alt-
hough theoretically promising, must be at this stage re-
garded with extreme caution and must always be
based on a broad knowledge of the biological idiosyn-
crasy of the type of tumour subject to treatment.
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